FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013972435> ?p ?o ?g. }

• W2013972435 endingPage "371.e7" @default.
• W2013972435 startingPage "360" @default.
• W2013972435 abstract "Background & AimsSevere polycystic liver disease can complicate adult dominant polycystic kidney disease, a genetic disease caused by defects in polycystin-1 (Pkd1) or polycystin-2 (Pkd2). Liver cyst epithelial cells (LCECs) express vascular endothelial growth factor (VEGF) and its receptor, VEGFR-2. We investigated the effects of VEGF on liver cyst growth and autocrine VEGF signaling in mice with Pkd1 and Pkd2 conditional knockouts.MethodsWe studied mice in which Pkd1 or Pkd2 were conditionally inactivated following exposure to tamoxifen; these mice were called Pkd1flox/−:pCxCreER (Pkd1KO) and Pkd2flox/−:pCxCreER (Pkd2KO).ResultsPkd1KO and Pkd2KO mice developed liver defects; their LCECs expressed VEGF, VEGFR-2, hypoxia-inducible factor (HIF)-1α, phosphorylated extracellular signal–regulated kinase 1/2 (pERK1/2), and proliferating cell nuclear antigen (PCNA). In Pkd2KO but not Pkd1KO mice, exposure to the VEGFR-2 inhibitor SU5416 significantly reduced liver cyst development, liver/body weight ratio, and expression of pERK and PCNA. VEGF secretion and phosphorylation of ERK1/2 and VEGFR-2 were significantly increased in cultured LCECs from Pkd2KO compared with Pkd1KO mice. Inhibition of protein kinase A (PKA) reduced VEGF secretion and pERK1/2 expression. Addition of VEGF to LCECs from Pkd2KO mice increased phosphorylated VEGFR-2 and phosphorylated mitogen signal-regulated kinase (MEK) expression and induced phosphorylation of ERK1/2; this was inhibited by SU5416. Expression of HIF-1α increased in parallel with secretion of VEGF following LCEC stimulation. VEGF-induced cell proliferation was inhibited by the MEK inhibitor U1026 and by ERK1/2 small interfering RNA.ConclusionsThe PKA–ERK1/2–VEGF signaling pathway promotes growth of liver cysts in mice. In Pkd2-defective LCECs, PKA-dependent ERK1/2 signaling controls HIF-1α–dependent VEGF secretion and VEGFR-2 signaling. Autocrine and paracrine VEGF signaling promotes the growth of liver cysts in Pkd2KO mice. VEGF inhibitors might be used to treat patients with polycystic liver disease. Severe polycystic liver disease can complicate adult dominant polycystic kidney disease, a genetic disease caused by defects in polycystin-1 (Pkd1) or polycystin-2 (Pkd2). Liver cyst epithelial cells (LCECs) express vascular endothelial growth factor (VEGF) and its receptor, VEGFR-2. We investigated the effects of VEGF on liver cyst growth and autocrine VEGF signaling in mice with Pkd1 and Pkd2 conditional knockouts. We studied mice in which Pkd1 or Pkd2 were conditionally inactivated following exposure to tamoxifen; these mice were called Pkd1flox/−:pCxCreER (Pkd1KO) and Pkd2flox/−:pCxCreER (Pkd2KO). Pkd1KO and Pkd2KO mice developed liver defects; their LCECs expressed VEGF, VEGFR-2, hypoxia-inducible factor (HIF)-1α, phosphorylated extracellular signal–regulated kinase 1/2 (pERK1/2), and proliferating cell nuclear antigen (PCNA). In Pkd2KO but not Pkd1KO mice, exposure to the VEGFR-2 inhibitor SU5416 significantly reduced liver cyst development, liver/body weight ratio, and expression of pERK and PCNA. VEGF secretion and phosphorylation of ERK1/2 and VEGFR-2 were significantly increased in cultured LCECs from Pkd2KO compared with Pkd1KO mice. Inhibition of protein kinase A (PKA) reduced VEGF secretion and pERK1/2 expression. Addition of VEGF to LCECs from Pkd2KO mice increased phosphorylated VEGFR-2 and phosphorylated mitogen signal-regulated kinase (MEK) expression and induced phosphorylation of ERK1/2; this was inhibited by SU5416. Expression of HIF-1α increased in parallel with secretion of VEGF following LCEC stimulation. VEGF-induced cell proliferation was inhibited by the MEK inhibitor U1026 and by ERK1/2 small interfering RNA. The PKA–ERK1/2–VEGF signaling pathway promotes growth of liver cysts in mice. In Pkd2-defective LCECs, PKA-dependent ERK1/2 signaling controls HIF-1α–dependent VEGF secretion and VEGFR-2 signaling. Autocrine and paracrine VEGF signaling promotes the growth of liver cysts in Pkd2KO mice. VEGF inhibitors might be used to treat patients with polycystic liver disease." @default.
• W2013972435 created "2016-06-24" @default.
• W2013972435 creator A5005614526 @default.
• W2013972435 creator A5012967730 @default.
• W2013972435 creator A5013568442 @default.
• W2013972435 creator A5034146725 @default.
• W2013972435 creator A5038287284 @default.
• W2013972435 creator A5045129998 @default.
• W2013972435 creator A5058175056 @default.
• W2013972435 creator A5077023498 @default.
• W2013972435 creator A5091430908 @default.
• W2013972435 date "2010-01-01" @default.
• W2013972435 modified "2023-10-18" @default.
• W2013972435 title "ERK1/2-Dependent Vascular Endothelial Growth Factor Signaling Sustains Cyst Growth in Polycystin-2 Defective Mice" @default.
• W2013972435 cites W1970193352 @default.
• W2013972435 cites W1971013426 @default.
• W2013972435 cites W1981606043 @default.
• W2013972435 cites W1986847155 @default.
• W2013972435 cites W1991488642 @default.
• W2013972435 cites W1991568191 @default.
• W2013972435 cites W1995201433 @default.
• W2013972435 cites W1995706631 @default.
• W2013972435 cites W1997273530 @default.
• W2013972435 cites W1999560996 @default.
• W2013972435 cites W2001988515 @default.
• W2013972435 cites W2002393978 @default.
• W2013972435 cites W2005717437 @default.
• W2013972435 cites W2012063336 @default.
• W2013972435 cites W2013620388 @default.
• W2013972435 cites W2013818100 @default.
• W2013972435 cites W2022911774 @default.
• W2013972435 cites W2025874902 @default.
• W2013972435 cites W2033197101 @default.
• W2013972435 cites W2041546338 @default.
• W2013972435 cites W2047025052 @default.
• W2013972435 cites W2048162979 @default.
• W2013972435 cites W2060121270 @default.
• W2013972435 cites W2061875834 @default.
• W2013972435 cites W2070558024 @default.
• W2013972435 cites W2073256310 @default.
• W2013972435 cites W2083881519 @default.
• W2013972435 cites W2085437068 @default.
• W2013972435 cites W2103908127 @default.
• W2013972435 cites W2107211482 @default.
• W2013972435 cites W2109179456 @default.
• W2013972435 cites W2112384663 @default.
• W2013972435 cites W2116601505 @default.
• W2013972435 cites W2125720034 @default.
• W2013972435 cites W2127325275 @default.
• W2013972435 cites W2129752592 @default.
• W2013972435 cites W2143816609 @default.
• W2013972435 cites W2147131783 @default.
• W2013972435 cites W2148684867 @default.
• W2013972435 cites W2150916555 @default.
• W2013972435 cites W2151925930 @default.
• W2013972435 cites W2158794894 @default.
• W2013972435 cites W2164030122 @default.
• W2013972435 cites W2164294210 @default.
• W2013972435 cites W2167881829 @default.
• W2013972435 cites W2171513678 @default.
• W2013972435 cites W4327766593 @default.
• W2013972435 doi "https://doi.org/10.1053/j.gastro.2009.09.005" @default.
• W2013972435 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3000794" @default.
• W2013972435 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19766642" @default.
• W2013972435 hasPublicationYear "2010" @default.
• W2013972435 type Work @default.
• W2013972435 sameAs 2013972435 @default.
• W2013972435 citedByCount "84" @default.
• W2013972435 countsByYear W20139724352012 @default.
• W2013972435 countsByYear W20139724352013 @default.
• W2013972435 countsByYear W20139724352014 @default.
• W2013972435 countsByYear W20139724352015 @default.
• W2013972435 countsByYear W20139724352016 @default.
• W2013972435 countsByYear W20139724352017 @default.
• W2013972435 countsByYear W20139724352018 @default.
• W2013972435 countsByYear W20139724352019 @default.
• W2013972435 countsByYear W20139724352020 @default.
• W2013972435 countsByYear W20139724352021 @default.
• W2013972435 countsByYear W20139724352022 @default.
• W2013972435 countsByYear W20139724352023 @default.
• W2013972435 crossrefType "journal-article" @default.
• W2013972435 hasAuthorship W2013972435A5005614526 @default.
• W2013972435 hasAuthorship W2013972435A5012967730 @default.
• W2013972435 hasAuthorship W2013972435A5013568442 @default.
• W2013972435 hasAuthorship W2013972435A5034146725 @default.
• W2013972435 hasAuthorship W2013972435A5038287284 @default.
• W2013972435 hasAuthorship W2013972435A5045129998 @default.
• W2013972435 hasAuthorship W2013972435A5058175056 @default.
• W2013972435 hasAuthorship W2013972435A5077023498 @default.
• W2013972435 hasAuthorship W2013972435A5091430908 @default.
• W2013972435 hasBestOaLocation W20139724352 @default.
• W2013972435 hasConcept C126322002 @default.
• W2013972435 hasConcept C128240485 @default.
• W2013972435 hasConcept C134018914 @default.
• W2013972435 hasConcept C146285616 @default.
• W2013972435 hasConcept C14858245 @default.
• W2013972435 hasConcept C167734588 @default.
• W2013972435 hasConcept C170493617 @default.

• next